Background Non-infectious intermediate uveitis, posterior uveitis and panuveitis are a
heterogeneous group of inflammatory eye disorders. Management includes local and …

Purpose: Report global adalimumab safety and efficacy outcomes in patients with non-
infectious uveitis. Methods: Adults with non-infectious intermediate, posterior, or panuveitis …

Background/aims To compare the efficacy of adalimumab in eyes with active and inactive
non-infectious uveitis in the real-world setting. Methods Multicentre, retrospective, chart …

Background Non-infectious non-anterior uveitis (NINA) is a sight-threatening condition that
often requires immunomodulatory drugs (IMDs) for its management. Objectives To evaluate …

Purpose To examine a large cohort of patients treated with biologic agents for active
noninfectious intermediate uveitis, posterior uveitis, or panuveitis (NIPPU) and to compare …

Background Patients with noninfectious uveitis are at risk for long-term complications of
uncontrolled inflammation, as well as for the adverse effects of long-term glucocorticoid …

Background Non-infectious uveitis is a potentially sight-threatening ocular disorder caused
by chronic inflammation and its complications. Therapeutic success is limited by systemic …

Objective To summarize updated evidences on the efficacy and safety of adalimumab (ADA)
in the treatment of patients with non-infectious uveitis. Patients and methods A systematic …

PURPOSE To compare the relapse rate of sight-threatening noninfectious uveitis (NIU) in
patients treated with infliximab (IFX) or adalimumab (ADA). DESIGN Observational …

Objective To establish the safety and efficacy of infliximab for the treatment of refractory
noninfectious uveitis. Design Retrospective, interventional, noncomparative cohort study …